LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Antibacterial Sonodynamic Therapy: Current Status and Future Perspectives.

    Roy, Jayishnu / Pandey, Vijayalakshmi / Gupta, Iti / Shekhar, Himanshu

    ACS biomaterials science & engineering

    2021  Volume 7, Issue 12, Page(s) 5326–5338

    Abstract: Multidrug-resistant bacteria have emerged in both community and hospital settings, partly due to the misuse of antibiotics. The inventory of viable antibiotics is rapidly declining, and efforts toward discovering newer antibiotics are not yielding the ... ...

    Abstract Multidrug-resistant bacteria have emerged in both community and hospital settings, partly due to the misuse of antibiotics. The inventory of viable antibiotics is rapidly declining, and efforts toward discovering newer antibiotics are not yielding the desired outcomes. Therefore, alternate antibacterial therapies based on physical mechanisms such as light and ultrasound are being explored. Sonodynamic therapy (SDT) is an emerging therapeutic approach that involves exposing target tissues to a nontoxic sensitizing chemical and low-intensity ultrasound. SDT can enable site-specific cytotoxicity by producing reactive oxygen species (ROS) in response to ultrasound, which can be harnessed for treating bacterial infections. This approach can potentially be used for both superficial and deep-seated microbial infections. The majority of the sonosensitizers reported are nonpolar, exhibiting limited bioavailability and a high clearance rate in the body. Therefore, targeted delivery agents such as nanoparticle composites, liposomes, and microbubbles are being investigated. This article reviews recent developments in antibacterial sonodynamic therapy, emphasizing biophysical and chemical mechanisms, novel delivery agents, ultrasound exposure and image guidance strategies, and the challenges in the pathway to clinical translation.
    MeSH term(s) Anti-Bacterial Agents/therapeutic use ; Liposomes ; Nanoparticles ; Reactive Oxygen Species ; Ultrasonic Therapy
    Chemical Substances Anti-Bacterial Agents ; Liposomes ; Reactive Oxygen Species
    Language English
    Publishing date 2021-10-29
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ISSN 2373-9878
    ISSN (online) 2373-9878
    DOI 10.1021/acsbiomaterials.1c00587
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Adjuvanted nanoliposomes displaying six hemagglutinins and neuraminidases as an influenza virus vaccine.

    Sia, Zachary R / Roy, Jayishnu / Huang, Wei-Chiao / Song, Yiting / Zhou, Shiqi / Luo, Yuan / Li, Qinzhe / Arpin, Dominic / Kutscher, Hilliard L / Ortega, Joaquin / Davidson, Bruce A / Lovell, Jonathan F

    Cell reports. Medicine

    2024  Volume 5, Issue 3, Page(s) 101433

    Abstract: Inclusion of defined quantities of the two major surface proteins of influenza virus, hemagglutinin (HA) and neuraminidase (NA), could benefit seasonal influenza vaccines. Recombinant HA and NA multimeric proteins derived from three influenza serotypes, ... ...

    Abstract Inclusion of defined quantities of the two major surface proteins of influenza virus, hemagglutinin (HA) and neuraminidase (NA), could benefit seasonal influenza vaccines. Recombinant HA and NA multimeric proteins derived from three influenza serotypes, H1N1, H3N2, and type B, are surface displayed on nanoliposomes co-loaded with immunostimulatory adjuvants, generating "hexaplex" particles that are used to immunize mice. Protective immune responses to hexaplex liposomes involve functional antibody elicitation against each included antigen, comparable to vaccination with monovalent antigen particles. When compared to contemporary recombinant or adjuvanted influenza virus vaccines, hexaplex liposomes perform favorably in many areas, including antibody production, T cell activation, protection from lethal virus challenge, and protection following passive sera transfer. Based on these results, hexaplex liposomes warrant further investigation as an adjuvanted recombinant influenza vaccine formulation.
    MeSH term(s) Mice ; Animals ; Humans ; Influenza Vaccines ; Hemagglutinins ; Neuraminidase/genetics ; Orthomyxoviridae Infections ; Influenza A Virus, H1N1 Subtype ; Influenza A Virus, H3N2 Subtype ; Liposomes ; Influenza, Human ; Adjuvants, Immunologic ; Vaccines, Synthetic
    Chemical Substances Influenza Vaccines ; Hemagglutinins ; Neuraminidase (EC 3.2.1.18) ; Liposomes ; Adjuvants, Immunologic ; Vaccines, Synthetic
    Language English
    Publishing date 2024-02-23
    Publishing country United States
    Document type Journal Article
    ISSN 2666-3791
    ISSN (online) 2666-3791
    DOI 10.1016/j.xcrm.2024.101433
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top